Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.
Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.
NexLife’s plan pages name three 503A pharmacies: Absolute Pharmacy in Lutz, Florida, Premium Compounding in Decatur, Alabama, and Boudreaux’s New Drug Store in Lake Charles, Louisiana.
No. 503B outsourcing facilities are FDA-registered and FDA-inspected and follow cGMP, but compounded medications from either 503A or 503B pathways are not FDA-approved drugs. Only manufactured brands such as Wegovy or Zepbound carry FDA approval.
A 503A pharmacy is state-licensed and overseen by the state pharmacy board. It compounds patient-specific preparations under valid prescriptions and follows USP <797> sterile compounding standards.
No. Retatrutide and cagrilintide cannot be used in compounding, whether at a 503A pharmacy or a 503B facility, so offers of compounded retatrutide should be treated as a warning sign.